- €499.32m
- €491.57m
- €788.37m
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases
Europe Research Roundup: ABN Amro Bank, Man Group, TP
Evotec extends losses after TD Cowen cuts to 'hold'
Europe Research Roundup: Adidas, Burkhalter Holding, Playtech
Live Markets: Half-time in Europe: looking tough
FY profit warning sends Evotec's shares to 10-yr lows
Evotec shares drop on guidance cut, 'ugly' Q2
Brief: Evotec Expects FY 2026 Group Revenues Of 570-610 Million Euros
Brief: Evotec Convertible Deal Expected To Price With 2.625% Coupon And 37.5% Conversion Premium,Bookrunner Says
Brief: Evotec Delta ABO Total Offering Size Up To C.40 Million EUR, Bookrunner Says
Brief: Evotec Convertible Books Covered On Delta Placement ABB (Indicated Demand Exceeds Deal Size), Says Bookrunner
Brief: Evotec Launches Around EUR 125 Mln Convertible Bond Offering
Germany's Evotec Q1 revenue falls on prior-year one-off
Brief: Evotec 2026 Guidance Confirmed
Brief: Evotec Q1 Operating Income EUR -103.599 Million
Brief: Evotec Announces Nomination Of First Preclinical Development Candidate In Dermatology Collaboration With Almirall